Palo Alto Networks Inc vs BIO-TECHNE Corp — how do they compare? Palo Alto Networks Inc trades at $335 (market cap $278.85B), while BIO-TECHNE Corp trades at $71.73 (market cap $11.16B). The key difference: Palo Alto Networks Inc is far larger — about 25× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.45% dividend while Palo Alto Networks Inc pays none. Which is the better fit depends on your goals.
| PANW | TECH | |
|---|---|---|
Market Cap | $278.85B | $11.16B |
Sector | Technology | Health |
52-Week High | $358.68 | $72.12 |
52-Week Low | $141.67 | $43.31 |
Enterprise Value | $277.81B | $11.24B |
Dividend Yield | — | 0.45% |
Signals from Pluang's Aura AI — not financial advice
Palo Alto Networks (PANW) trades at $342.15, down 4.61% today, yet maintains a bullish technical trend with strong analyst support. Recent earnings consistently beat expectations, with Q1 2026 EPS of $0.85 surpassing the $0.793 estimate. The company shows robust revenue growth, reaching $9.22B in 2025, and positive cash flow trends, though valuation ratios like a P/E of 303.18 remain elevated. News highlights focus on AI-driven cybersecurity demand and strategic acquisitions, such as the intent to enhance its observability platform announced on July 21, 2026.
Outlook is positive due to strong market positioning in cybersecurity and AI integration, but high valuations and competitive pressures pose risks. Investment opportunity lies in sustained earnings growth and sector tailwinds, while investors should monitor execution on guidance and margin sustainability.
Bio-Techne (TECH) trades at $71.63, down 0.68% on the day, near its all-time high following a $73 per share acquisition offer from Merck KGaA. The stock shows bullish technical signals with strong moving averages and ADX trends. Fundamentally, the company reported mixed quarterly earnings but maintains solid gross margins of 64.96%. Recent news is dominated by the proposed $11.3 billion buyout, driving significant investor interest and legal scrutiny over the transaction's fairness.
The outlook is heavily influenced by the pending acquisition, with upside capped near the $73 offer price. Risks include shareholder litigation and regulatory approval delays. Analyst consensus is split evenly between Buy and Hold, reflecting uncertainty around deal completion. The stock presents a potential arbitrage opportunity if the acquisition proceeds, but carries event risk if the transaction fails.
Trailing returns across standard periods
Latest headlines on both assets
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →